¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Charcot disease"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • secondary disease
    ¼Ó¹ßº´, ¼Ó¹ßÁúȯ
  • self-limited disease
    ÀڱⱹÇѺ´
  • septic disease
    ÆÐÇ÷º´
  • severe combined immunodeficiency disease
    ÁßÁõº¹Çո鿪°áÇ̺´
  • sexually transmitted disease
    ¼º¸Å°³º´, ¼ºº´
  • sickle cell disease
    ³´ÀûÇ÷±¸º´
  • Sandhoff¡¯s disease
    ÀÜÆ®È£ÇÁº´
  • silo filler¡¯s disease
    »çÀϷγóºÎº´, ¸¶ÃÊÀúÀå°í³óºÎº´
  • Simmonds¡¯ disease
    ½Ã¸ÕÁ
  • sleeping disease
    ¼ö¸éº´
  • Takayasu¡¯s disease
    ´ÙÄ«¾ß½ºº´
  • Tangier disease
    źÁö¿¡¸£º´
  • Unverricht¡¯s disease
    ¿îº£¸®È÷Æ®º´
  • upper motor neuron disease
    À§¿îµ¿½Å°æ¼¼Æ÷º´, »óÀ§¿îµ¿½Å°æ¿øº´
  • upper respiratory disease
    »ó±âµµº´
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • hemoglobin M disease
    Çì¸ð±Û·Îºó Mº´.
  • hemoglobin M disease
    Çì¸ð±Û·Îºó Mº´
  • hemoglobin SC disease
    Çì¸ð±Û·Îºó SC º´
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SDº´.
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SD º´
  • hemoglobin SD disease
    Çì¸ð±Û·Îºó SDº´
  • hemoglobin h disease
    Ç÷»ö¼Ò H º´
  • hemoglobinopathy =abnormal hemoglobin disease
    Ç÷»ö¼Òº´Áõ.
  • hemolytic disease
    ¿ëÇ÷¼º Áúȯ(¡­òðü´).
  • hemolytic disease
    ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of fetus/newborn
    žÆ/½Å»ý¾Æ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemolytic disease of newborn
    ½Å»ý¾Æ ¿ëÇ÷¼º Áúȯ
  • hemolytic disease of newborn
    ½Å»ý¾Æ¿ëÇ÷¼º Áúȯ.
  • hemorrhagic disease
    ÃâÇ÷(¼º) Áúȯ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´
  • foot and mouth disease
    ±¸Àúº´
  • foot and mouth disease
    ¹ßÀÔº´, Á·±¸º´.
  • foot process disease
    Á·¼¼Æ÷ µ¹±âº´
  • foot-and-mouth disease
    ±¸Á¦¿ª (Ï¢ð´æ¹)
  • frozen shoulder =Duplay s disease
    µ¿°á°ß, µ¿°ß°üÀý, À¯Âø¼º °ß °üÀý¸·¿°,¿À½Ê ¾î±ú, µ¿Å뼺 °ß±¸Ãà(Áõ)(ÔÙ÷Ôàõ̷Ϭõêñø), µàÇ÷¹À̺´ .
  • functional cardiovascular disease
    ±â´É¼º ½ÉÇ÷°üº´.
  • fungal disease
    Áø±Õº´(òØÐ¶Ü»).
  • fungal disease
    Áø±ÕÁúȯ(¡­òðü´)
  • fungal disease,deep
    ½ÉºÎ
  • fungal disease,encephalitic
    ³ú¿°¼º(Òàæúàõ)
  • fungal disease,superficial
    Ç¥À缺(øúî¤àõ)
  • fungous disease
    Áø±ÕÁúȯ, °õÆÎÀÌÆò
  • gamma heavy chain disease
    °¨¸¶Á߼⺴(¡­ñìáðÜ»).
  • gamma heavy chain disease
    °¨¸¶Á߼⺴
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
COLD Chronic Obstructive Lung Disease
COPD Chronic Obstructive Pulmonary Disease; ¸¸¼º Æó¼â¼º ÆóÁúȯ
CTD Connective Tissue Disease
DDD Degenerative Disc Disease
DILD Diffuse Interstitial Lung Disease; ¹Ì¸¸¼º °£Áú¼º ÆóÁúȯ
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 20
DAI Disease Activity Index
DAS Disease Activity Score
DM Disease Management
DMARD Disease Modifying Antirheumatic Drugs
DFS Disease free
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • woolsorters disease
    ¾ç¸ð¾÷ÀÚº´
    ¾ç¸ð¸¦ Ãë±ÞÇÏ´Â »ç¶÷¿¡¼­ º¼ ¼ö ÀÖ´Â ÆóÀÇ ÅºÀú·Î, B. anthrax¸¦ ÈíÀÔÇÔÀ¸·Î½á ÀϾ´Ù.
  • Zahorsky's disease
    ÀÚÈ£¸£½ºÅ° º´
    À¯¾Æ¿¡¼­ º¼ ¼ö ÀÖ´Â µ¹¹ß¼º ¹ßÁø.
  • Ziehen-Oppengeim disease
    Á¦¿£-¿ÀÆæÇÏÀÓº´
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 20
medullary cystic disease <disease> A rare hereditary kidney disease characterised by the gradual loss of kidney function due to the presence of cysts in the renal medulla.
Symptoms include high urine output (cannot concentrate the urine), weakness, weight loss, nocturia, fatigue and headache. There is no cure and usually progresses from chronic renal failure to end stage renal disease.
(27 Sep 1997)
medullary cystic kidney disease <radiology> Mode of inheritance uncertain, usually affects young adults (early 20s), associated with red or blond hair (!!), causes salt wasting, polyuria, azotaemia, affects both kidneys, with progressive disease patients need dialysis or transplant
(12 Dec 1998)
central Recklinghausen's disease type II type 1 neurofibromatosis
Centres for Disease Control The federal facility for disease eradication, epidemiology, and education headquartered in Atlanta, Georgia, which encompasses the Centre for Infectious Diseases, Centre for Environmental Health, Centre for Health Promotion and Education, Centre for Prevention Services, Centre for Professional Development and Training, and Centre for Occupational Safety and Health. Formerly named Centre for Disease Control (1970), Communicable Disease Centre (1946).
(05 Mar 2000)
centres for disease control and prevention See: CDC.
(12 Dec 1998)
Voltolini's disease Disease of the labyrinth, leading to deafmutism, in young children.
(05 Mar 2000)
Pel-Ebstein disease The remittent fever common in Hodgkin's disease.
Synonym: Pel-Ebstein disease.
(05 Mar 2000)
Pelizaeus-Merzbacher disease A sudanophilic leukodystrophy with a tigroid appearance of the myelin resulting from patchy demyelination. Type 1-classic, nystagmus and tremor appearing in the first few months of life, followed by slow motor development sometimes with choreoathetosis, spasticity, optic atrophy and seizures, with death in early adulthood, X-linked recessive inheritance; type 2-contralateral form with death in months to years after birth, X-linked recessive inheritance; type 3-transitional, with death in the first decade; type 4-adult form associated with involuntary movements, ataxia and hyperreflexia, but without nystagmus; type 5-variant forms. Cockayne is sometimes included as a sixth form.
Synonym: Merzbacher-Pelizaeus disease.
(05 Mar 2000)
Pellegrini's disease A calcific density in the medial collateral ligament and/or bony growth at the internal condyle of the femur.
Synonym: Pellegrini-Stieda disease.
(05 Mar 2000)
Pellegrini-Stieda disease A calcific density in the medial collateral ligament and/or bony growth at the internal condyle of the femur.
Synonym: Pellegrini-Stieda disease.
(05 Mar 2000)
glycogen storage disease <hepatology> A group of inherited metabolic disorders involving the enzymes responsible for the synthesis and degradation of glycogen. In some patients, prominent liver involvement is presented. In others, more generalised storage of glycogen occurs, sometimes with prominent cardiac involvement.
Synonym: glycogenosis
(12 Sep 2002)
glycogen storage disease type I <disease> An autosomal recessive disease in which gene expression of glucose-6-phosphatase is absent, resulting in hypoglycaemia due to lack of glucose production.
Accumulation of glycogen in liver and kidney leads to organomegaly, particularly massive hepatomegaly. Increased concentrations of lactic acid and hyperlipidemia appear in the plasma. Clinical gout often appears in early childhood.
Inheritance: autosomal recessive.
(12 Dec 1998)
glycogen storage disease type II <disease> Glycogenosis due to alpha-1,4-glucosidase (acid maltase) deficiency. It affects muscle, heart, and other organs.
(12 Dec 1998)
glycogen storage disease type III <disease> An autosomal recessive metabolic disorder due to deficient expression of amylo-1,6-glucosidase (one part of the glycogen debranching enzyme system).
The clinical course of the disease is similar to that of glycogen storage disease type I, but milder. Massive hepatomegaly, which is present in young children, diminishes and occasionally disappears with age. Levels of glycogen with short outer branches are elevated in muscle, liver, and erythrocytes. Six subgroups have been identified, with subgroups type IIIa and type IIIb being the most prevalent.
Inheritance: autosomal recessive
(12 Dec 1998)
glycogen storage disease type IV <disease> An autosomal recessive metabolic disorder due to a deficiency in expression of branching enzyme (alpha-1,4-glucan-6-alpha-glucosyltransferase), resulting in an accumulation of abnormal glycogen with long outer branches. Clinical features are muscle hypotonia and cirrhosis. Death from liver disease usually occurs before age 2.
Inheritance: autosomal recessive
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 20
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 20
ÅëÇÕ°Ë»ö ¿Ï·á